KAPJOMI
Live / Allowed — Third extension granted (statement of use) (as of 15 Jun 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 09 Apr 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98491024
- Mark type
- Word mark
- Filed
- 09 Apr 2024
- Published for opposition
- 26 Nov 2024
- Attorney of record
- Danielle Rivera
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 16 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Jun 2026 — SOU EXTENSION 3 GRANTED
- 15 Jun 2026 — SOU EXTENSION 3 FILED
- 15 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Dec 2025 — SOU EXTENSION 2 GRANTED
- 09 Dec 2025 — SOU EXTENSION 2 FILED
- 09 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Jun 2025 — SOU EXTENSION 1 GRANTED
- 17 Jun 2025 — SOU EXTENSION 1 FILED
- 17 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Nov 2024 — PUBLISHED FOR OPPOSITION